All In Biotech

Drug Trial Radar · NCT07220109

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

A Phase 3, Randomized, Controlled, Observer Blind, Immuno-bridging Study to Evaluate Immunogenicity, Reactogenicity, Safety of a Single Dose of GSK's RSVPreF3 OA Investigational Vaccine in Chinese Adults 18-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

750

Actual

Start

Oct 29, 2025

Primary completion

Jul 20, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the immune response of the RSVPreF3 OA investigational vaccine in Chinese adults 18 to 59 years of age (YOA) who are at increased risk of respiratory syncytial virus (RSV) disease, in comparison with the immune response generated in older adults 60 YOA and above from the 219815 (RSV OA=ADJ-021; NCT06551181) study following a single dose of the RSVPreF3 OA vaccine. In addition, the safety and reactogenicity of the vaccine will also be assessed.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA vaccineBiological

    1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

  • PlaceboBiological

    1 dose of saline solution administered intramuscularly in the deltoid region of the non-dominant arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RSV-A neutralizing titers expressed as group Geometric Mean Titers (GMTs)Time frame: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)
  2. RSV-A neutralizing titers expressed as group Seroresponse rate (SRR)Time frame: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)
  3. RSV-B neutralizing titers expressed as group GMTsTime frame: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)
  4. RSV-B neutralizing titers expressed as group SRRTime frame: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Chengdu, China

  • GSK Investigational Site

    Chongqing, China

  • GSK Investigational Site

    Chongqing, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Jiujiang, China

  • GSK Investigational Site

    Kunming, China

  • GSK Investigational Site

    Nanning, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Zhuhai, China

  • GSK Investigational Site

    Beijing, Beijing Municipality, China

  • GSK Investigational Site

    Xiangtan, Hunan, China

  • GSK Investigational Site

    Nanjing, Jiangsu, China

  • GSK Investigational Site

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.